A look toward the future treatment of advanced renal cell carcinoma.
Robert J. Motzer, MD: There’s always a need for novel agents in renal cell cancer and other malignancies. For the most part, the drugs we use are all based on either TKIs [tyrosine kinase inhibitors] or I/O [immuno-oncology] therapies—M2s in certain instances— so we’re looking for a new mechanism of action. The novel compound that I see as the most promising, that’s coming down the pike, is the new HIF inhibitor, MK-6482. That has shown activity in heavily pretreated patients. It looks to be relatively well tolerated. It’s being compared with everolimus in heavily pretreated patients. MK-6482 is also being studied in combination. There’s a large phase 3 trial that we’re initiating that compares lenvatinib plus MK-6482 with cabozantinib in second- or third-line therapy, in patients who have had prior immunotherapy and progressed. This is an area of unmet need because the landscape has changed so rapidly. We need to better identify the best therapies for patients who progressed on I/O therapy, and a good candidate for that will be MK-6482.
Transcript edited for clarity.
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
May 6th 2024The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for February 28, 2025.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Tolerability Helps Decide Third-Line Treatment in Advanced RCC
April 30th 2024During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.
Read More
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More